Ségolène Siméon, 2021-2023
Ségolène Siméon is a postdoctoral fellow working with Prof. Rada Savic at UCSF. She completed her PharmD with a specialization in pharmacometrics at Paris Descartes University. For her PhD research, Ségolène studied the developmental toxicity of zebrafish embryo exposed to teratogen compounds, with the development of two mathematical models. She is currently working on dosing regimen optimization in young malnourished children with malaria disease and studying the malnutrition impact on treatment failure. Predictions allow to inform if the actual dosing regimen recommendations are suitable or if adjustments must be done for at risk populations. During the fellowship, Ségolène will be pursuing her research in the clinical pharmacology field to optimize drug use and effect with pharmacometrics tools. As a CERSI scholar, she will continue to develop her modeling skills and apply them to the different phases of drug clinical development. She will also learn about drug development protocol and clinical study design.
Huy Ngo, 2020-2022
Huy Ngo received a Pharm.D. from Massachusetts College of Pharmacy and Health Sciences and a Ph.D. from University of Kentucky. Subsequently, Huy started his postdoctoral training in transporter biology under the mentorship of Prof. Kathy Giacomini at University of California, San Francisco (UCSF). Huy hopes to leverage his clinical pharmacy and transporter biology training to advance methods in clinical pharmacology study design and drug assessment. As a CERSI fellow, he had the opportunity to develop a population pharmacokinetics model to optimize rifampicin dosing under the guidance of Prof. Rada Savic at UCSF. He also contributed to the design of a clinical study to assess the impact of an excipient on drug absorption under the supervision of Prof. Kathy Giacomini. Currently, Huy is completing his industry rotation in the clinical pharmacology department at Genentech.
Obi Okafor, 2017-2019
Obi Okafor is originally from Los Angeles, California. He completed his Doctorate of Pharmacy at Howard University in Washington DC. As a student, he spent time researching the effects of non-cardiac drugs on cardiac rhythm. During his final year, he completed a regulatory science project at the FDA involving the use of gadolinium in MRI based contrast agents. At UCSF, Obi hopes to train under Dr. Kathleen Giacomini on emerging regulatory science challenges surrounding excipient use in generic drugs. Obi believes the CERSI fellowship will be a great opportunity and is curious to witness how best to integrate regulation in science to really drive innovation. His professional interests include patient advocacy and evaluating the current role of biosimilars in healthcare as therapeutic alternatives. In his spare time Obi enjoys watching sports, spending time with family and friends and catching up on sleep.
Kathy Cheung, 2016-2019
Kathy Cheung received her Pharm.D. degree from the University of California, San Francisco in 2016. A student pharmacist in the pharmaceutical sciences pathway, she completed a pharmacogenomics research project that aimed to elucidate the genetic factors that are associated with the suboptimal therapeutic response to allopurinol in gout patients. Kathy is currently working on a regulatory science project on medical countermeasures under the direct mentorship of Dr. Kathleen Giacomini. Specifically, she is interested in characterizing the differences in the expression levels and activities of renal membrane transporter in special populations, and how such differences will affect drug absorption and disposition. As a UCSF-Stanford CERSI postdoctoral fellow, Kathy is curious to learn how the academia, industry and regulatory agencies work together to translate health care innovations and scientific findings to practical applications in patient care while ensuring safety and efficacy.
Jennifer Wilson, 2016-2019
Jennifer Wilson is a postdoc in Russ Altman's lab at Stanford. Her interest in science for policy started when she was an undergraduate at the University of Virginia where she minored in science policy and participated in a science policy internship in Washington D.C. Since that time, Jen completed her Ph.D. at MIT in Bioengineering where she investigated how to use network methods to better understand shRNA screens. At Stanford, Jen is interested in extending network methods to improve understanding of drug mechanisms and aid in drug repurposing efforts. The CERSI program was a natural fit given her enthusiasm for using science to solve problems across multiple interests groups - especially solving problems that bridge academic and policy challenges. She's also an enthusiastic cyclist and enjoys mentoring other students interested in pursuing careers in science.